It also shows that potential downstream mechanisms such as tau, neuroinflammation, and neurodegeneration are very early mechanisms that occur before or around the threshold for abnormal amyloid deposition (“amyloid positivity”), which may be important to consider when designing clinical AD trials. Here, MAPT is linked to Alzheimer disease.